Microtubule organization and dynamics are essential during axon and dendrite formation and maintenance in neurons. However, little is known about the regulation of microtubule dynamics during synaptic development and function in mammalian neurons. Here, we present evidence that the microtubule plus-end tracking protein CLASP2 (cytoplasmic linker associated protein 2) is a key regulator of axon and dendrite outgrowth that leads to functional alterations in synaptic activity and formation. We found that CLASP2 protein levels steadily increase throughout neuronal development in the mouse brain and are specifically enriched at the growth cones of extending neurites. The shRNA-mediated knockdown of CLASP2 in primary mouse neurons decreased axon and dendritic length whereas overexpression of human CLASP2 caused the formation of multiple axons, enhanced dendritic branching, and Golgi condensation, implicating CLASP2 in neuronal morphogenesis. In addition, the CLASP2-induced morphological changes led to significant functional alterations in synaptic transmission. CLASP2 overexpression produced a large increase in spontaneous miniature event frequency that was specific to excitatory neurotransmitter release. The changes in presynaptic activity produced by CLASP2 overexpression were accompanied by increases in presynaptic terminal circumference, total synapse number and a selective increase in presynaptic proteins that are involved in neurotransmitter release. Also, we found a smaller increase in miniature event amplitude that was accompanied by an increase in postsynaptic surface expression of GluA1 receptor localization. Together, these results provide evidence for involvement of the microtubule plus-end tracking protein CLASP2 in cytoskeleton-related mechanisms underlying neuronal polarity and interplay between the microtubule stabilization and synapse formation and activity.
Structural analysis of the known
NIK inhibitor 3 bound
to the kinase domain of TTBK1 led to the design and synthesis of a
novel class of azaindazole TTBK1 inhibitors exemplified by 8 (cell IC50: 571 nM). Systematic optimization of this
series of analogs led to the discovery of 31, a potent
(cell IC50: 315 nM) and selective TTBK inhibitor with suitable
CNS penetration (rat Kp,uu: 0.32) for in vivo proof of
pharmacology studies. The ability of 31 to inhibit tau
phosphorylation at the disease-relevant Ser 422 epitope was demonstrated
in both a mouse hypothermia and a rat developmental model and provided
evidence that modulation of this target may be relevant in the treatment
of Alzheimer’s disease and other tauopathies.
Background: Activity-dependent amyloid  (A) generation requires endosomal proteolytic cleavage of the amyloid precursor protein (APP). Results: Mints are adaptor proteins that regulate APP endocytosis and insertion at the plasma membrane upon activity induction or inhibition. Conclusion: Mints are necessary for activity-induced APP trafficking and A generation. Significance: Insight into the cell biology and molecules controlling APP trafficking is essential in understanding A pathogenesis.
SUMMARY
The Reelin signaling pathway plays a crucial role in regulating neocortical development. However, little is known about how Reelin controls the cytoskeleton during neuronal migration. Here, we identify CLASP2 as a key cytoskeletal effector in the Reelin signaling pathway. We demonstrate that CLASP2 has distinct roles during neocortical development regulating neuron production and controlling neuron migration, polarity, and morphogenesis. We found down-regulation of CLASP2 in migrating neurons leads to mislocalized cells in deeper cortical layers, abnormal positioning of the centrosome-Golgi complex, and aberrant length/orientation of the leading process. We discovered Reelin regulates several phosphorylation sites within the positively-charged serine/arginine rich region that constitute consensus GSK3β phosphorylation motifs of CLASP2. Furthermore, phosphorylation of CLASP2 regulates its interaction with the Reelin adaptor Dab1 and this association is required for CLASP2 effects on neurite extension and motility. Together, our data reveal CLASP2 is an essential Reelin effector orchestrating cytoskeleton dynamics during brain development.
Hyperphosphorylated tau protein is a pathological hallmark of numerous neurodegenerative diseases and the level of tau pathology is correlated with the degree of cognitive impairment. Tau hyper-phosphorylation is thought to be an early initiating event in the cascade leading to tau toxicity and neuronal death. Inhibition of tau phosphorylation therefore represents an attractive therapeutic strategy. However, the widespread expression of most kinases and promiscuity of their substrates, along with poor selectivity of most kinase inhibitors, have resulted in systemic toxicities that have limited the advancement of tau kinase inhibitors into the clinic. We therefore focused on the CNS-specific tau kinase, TTBK1, and investigated whether selective inhibition of this kinase could represent a viable approach to targeting tau phosphorylation in disease. In the current study, we demonstrate that TTBK1 regulates tau phosphorylation using overexpression or knockdown of this kinase in heterologous cells and primary neurons. Importantly, we find that TTBK1-specific phosphorylation of tau leads to a loss of normal protein function including a decrease in tau-tubulin binding and deficits in tubulin polymerization. We then describe the use of a novel, selective small molecule antagonist, BIIB-TTBK1i, to study the acute effects of TTBK1 inhibition on tau phosphorylation in vivo. We demonstrate substantial lowering of tau phosphorylation at multiple sites implicated in disease, suggesting that TTBK1 inhibitors may represent an exciting new approach in the search for neurodegenerative disease therapies. Significance statement The results described here are of significance because they represent the first demonstration, to our knowledge, that acute inhibition of TTBK1 with a small molecule inhibitor can lead to significant reductions in tau phosphorylation in vivo. In addition, our data implicates TTBK1 as the major kinase responsible for the phosphorylation of tau at S422 in the brain, a modification almost completely absent from normal adults but significantly elevated across a multitude of neurodegenerative diseases. Therefore, we believe that due to the CNS restricted expression of TTBK1, pharmacological inhibition of this kinase represents a promising therapeutic approach in the treatment of tauopathies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.